Heterocyclic substituted carbonyl derivatives and their use as dopamine d3 receptor ligands
CA 2438264 A1 · Owner: Chiang, Yulin · Inventors: Sabuco, Jean-Francois; Lee, George E.; Fink, David M.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D3 receptors. In another aspect the , invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse Dyskinetic Disorders (e.g. , Parkinson s Disease Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 15, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 15, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 15, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.